TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) is a common malignancy. Despite progress in treatment, HCC is still one of the most lethal cancers. Therefore, deepening molecular mechanisms underlying HCC pathogenesis and development is required to uncover new therapeutic strategies. Metabolic reprogramming is emerging as a critical player in promoting tumor survival and proliferation to sustain increased metabolic needs of cancer cells. Among the metabolic pathways, the tricarboxylic acid (TCA) cycle is a primary route for bioenergetic, biosynthetic, and redox balance requirements of cells. In recent years, a large amount of evidence has highlighted the relevance of the TCA cycle rewiring in a variety of cancers. Indeed, aberrant gene expression of several key enzymes and changes in levels of critical metabolites have been observed in many solid human tumors. In this review, we summarize the role of the TCA cycle rewiring in HCC by reporting gene expression and activity dysregulation of enzymes relating not only to the TCA cycle but also to glutamine metabolism, malate/aspartate, and citrate/pyruvate shuttles. Regarding the transcriptional regulation, we focus on the link between NF-κB-HIF1 transcriptional factors and TCA cycle reprogramming. Finally, the potential of metabolic targets for new HCC treatments has been explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 15×
“Consequently, NADH accumulation and chain respiratory alteration facilitate this conversion.”
BackgroundInfluentialCani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819 · cited 1×
“Of note, HSCs as well as hepatocytes and KCs also express TLR4—the most important LPS receptor—and activate NF-κB pathway following changes in gut microbiota, increased intestinal permeability and raised blood levels of LPS in mice fed a high-fat diet [46].”
BackgroundJones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Succinate is an inflammatory signal that induces IL-1β through HIF-1α
Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C., Bernard, N. J., Kelly, B., Foley, N. H., et al. (2013) · Nature · doi:10.1038/nature11986 · Cited by 4,176
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · cited 1×
“Furthermore, in the presence of low oxygen, HIF-1 transactivates PDK1 gene, encoding pyruvate dehydrogenase kinase 1, which phosphorylates and inhibits pyruvate dehydrogenase (PDH) complex thus reducing mitochondrial acetyl-CoA and increasing both pyruvate and lactate levels [59].”
BackgroundHypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“For example, citrate—the first intermediate of TCA cycle—is exported from mitochondria to the cytosol through the mitochondrial citrate carrier (CIC) resulting vital for de novo biosynthesis of fatty acids dramatically raised in cancer cells [17].”
BackgroundXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 1×
“These mutations result in the gained function producing the oncometabolite D-2-hydroxyglutarate (D-2-HG), which induces decreased levels of 5-hydroxymethylcytosine (5-HmC) by inhibiting Ten-eleven translocation (TET) family of 5-methylcitosine (5-mC) hydroxylases, an αKG dependent dioxygenase (Figure 2) [78].”
BackgroundDeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB
Cai, D., Yuan, M., Frantz, D. F., Melendez, P. A., Hansen, L., Lee, J., & Shoelson, S. E. (2005) · Nature Medicine · doi:10.1038/nm1166 · Cited by 2,245
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 2×
“Increased levels of succinate activate HIF-1 which in turn up-regulates metabolic genes switching to the Warburg effect [26].”
BackgroundReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791 · cited 1×
“Of note, glutamine-derived αKG may also provide citrate by a reductive carboxylation [16].”
BackgroundMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638 · cited 1×
“Mutations in genes encoding different subunits of SDH have been associated with succinate accumulation and are causative of hereditary paraganglioma and pheochromocytoma [94].”
BackgroundReductive carboxylation supports growth in tumour cells with defective mitochondria
Mullen, A. R., Wheaton, W. W., Jin, E. S., Chen, P.-H., Sullivan, L. B., Cheng, T., Yang, Y., Linehan, W. M., Chandel, N. S., & DeBerardinis, R. J. (2012) · Nature · doi:10.1038/nature10642 · Cited by 1,328
Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells
Sullivan, L. B., Gui, D. Y., Hosios, A. M., Bush, L. N., Freinkman, E., & Vander Heiden, M. G. (2015) · Cell · doi:10.1016/j.cell.2015.07.017 · Cited by 1,173
Quantitative flux analysis reveals folate-dependent NADPH production
Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B., & Rabinowitz, J. D. (2014) · Nature · doi:10.1038/nature13236 · Cited by 1,114
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer
Gross, M. I., Demo, S. D., Dennison, J. B., Chen, L., Chernov-Rogan, T., Goyal, B., Janes, J. R., Laidig, G. J., Lewis, E. R., Li, J., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0870 · Cited by 1,068
Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
McKeown, S. R. (2014) · The British Journal of Radiology · doi:10.1259/bjr.20130676 · Cited by 1,050 · cited 1×
“Significantly, reduced concentration of oxygen in many human cancers [57]—compared to adjacent normal tissues—activates HIFα.”
BackgroundIsaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958
Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi227 · Cited by 865
SDH mutations establish a hypermethylator phenotype in paraganglioma
Letouzé, E., Martinelli, C., Loriot, C., Burnichon, N., Abermil, N., Ottolenghi, C., Janin, M., Menara, M., Nguyen, A. T., Benit, P., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.018 · Cited by 776
Regulation of hypoxia-inducible factor-1α by NF-κB
van Uden, P., Kenneth, N. S., & Rocha, S. (2008) · Biochemical Journal · doi:10.1042/bj20080476 · Cited by 729 · cited 1×
“Of note, through IκBα degradation, hypoxia also activates NF-κB [50] which binds to HIF-1α gene promoter thus regulating its transcription (Figure 1) [51].”
BackgroundFatty acid carbon is essential for dNTP synthesis in endothelial cells
Schoors, S., Bruning, U., Missiaen, R., Queiroz, K. C. S., Borgers, G., Elia, I., Zecchin, A., Cantelmo, A. R., Christen, S., Goveia, J., et al. (2015) · Nature · doi:10.1038/nature14362 · Cited by 646
The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type
Yuneva, M. O., Fan, T. W. M., Allen, T. D., Higashi, R. M., Ferraris, D. V., Tsukamoto, T., Matés, J. M., Alonso, F. J., Wang, C., Seo, Y., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.015 · Cited by 639 · cited 2×
“It has been reported that cultured cancer cells may require up to 100-fold molar excess of glutamine compared to other amino acids [11] and glutamine deprivation from the tumor environment has been found in a variety of tumorigenic contexts [12,13].”
BackgroundKAT2A coupled with the α-KGDH complex acts as a histone H3 succinyltransferase
Wang, Y., Guo, Y. R., Liu, K., Yin, Z., Liu, R., Xia, Y., Tan, L., Yang, P., Lee, J.-H., Li, X.-J., et al. (2017) · Nature · doi:10.1038/nature25003 · Cited by 567 · cited 1×
“When α-KGDH complex does not enter the nucleus, or KAT2A gene expression is reduced, inhibition of tumor cell proliferation and tumor growth was observed [92].”
BackgroundTracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells
Lewis, C. A., Parker, S. J., Fiske, B. P., McCloskey, D., Gui, D. Y., Green, C. R., Vokes, N. I., Feist, A. M., Vander Heiden, M. G., & Metallo, C. M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.008 · Cited by 562
DeWaal, D., Nogueira, V., Terry, A. R., Patra, K. C., Jeon, S.-M., Guzman, G., Au, J., Long, C. P., Antoniewicz, M. R., & Hay, N. (2018) · Nature Communications · doi:10.1038/s41467-017-02733-4 · Cited by 525
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis
Xiang, Y., Stine, Z. E., Xia, J., Lu, Y., O’Connor, R. S., Altman, B. J., Hsieh, A. L., Gouw, A. M., Thomas, A. G., Gao, P., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75836 · Cited by 409
Bardella, C., Pollard, P. J., & Tomlinson, I. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.07.003 · Cited by 395 · cited 1×
“Mutations in SDH genes were identified in several other cancers including thyroid, gastrointestinal stromal, neuroblastoma, renal and ovarian cancer [96].”
BackgroundDiversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis
Rabinovich, S., Adler, L., Yizhak, K., Sarver, A., Silberman, A., Agron, S., Stettner, N., Sun, Q., Brandis, A., Helbling, D., et al. (2015) · Nature · doi:10.1038/nature15529 · Cited by 382
Oldham, W. M., Clish, C. B., Yang, Y., & Loscalzo, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.021 · Cited by 364 · cited 1×
“Thus, αKG-dependent PHDs would be regulated by L-2-HG/αKG ratio as αKG supplementation or KGDHC inhibition leads to a low increase of L-2-HG levels in normoxia condition, and high increase in hypoxia condition [91].”
BackgroundTargeting ASCT2‐mediated glutamine uptake blocks prostate cancer growth and tumour development
Wang, Q., Hardie, R., Hoy, A. J., van Geldermalsen, M., Gao, D., Fazli, L., Sadowski, M. C., Balaban, S., Schreuder, M., Nagarajah, R., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4518 · Cited by 338
Eagle, H. (1955) · The Journal of Experimental Medicine · doi:10.1084/jem.102.5.595 · Cited by 323 · cited 1×
“It has been reported that cultured cancer cells may require up to 100-fold molar excess of glutamine compared to other amino acids [11] and glutamine deprivation from the tumor environment has been found in a variety of tumorigenic contexts [12,13].”
BackgroundCancer-associated IDH mutations: biomarker and therapeutic opportunities
Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R. (2010) · Oncogene · doi:10.1038/onc.2010.444 · Cited by 296 · cited 1×
“IDH1 and/or IDH2 mutations occur in glioma, and rarely in other cancers [75,76].”
BackgroundMechanism of the Prolyl Hydroxylase Reaction: 2. Kinetic Analysis of the Reaction Sequence
MYLLYLÄ, R., TUDERMAN, L., & KIVIRIKKO, K. I. (1977) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1977.tb11889.x · Cited by 263
Yogev, O., Yogev, O., Singer, E., Shaulian, E., Goldberg, M., Fox, T. D., & Pines, O. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000328 · Cited by 220
Targeting Glutamine Induces Apoptosis: A Cancer Therapy Approach
Chen, L., & Cui, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160922830 · Cited by 184
Patel, D., Menon, D., Bernfeld, E., Mroz, V., Kalan, S., Loayza, D., & Foster, D. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.710145 · Cited by 86
Amino acid metabolism in tumour-bearing mice
Rivera, S., Azcón-Bieto, J., López-Soriano, F. J., Miralpeix, M., & Argilés, J. M. (1988) · Biochemical Journal · doi:10.1042/bj2490443 · Cited by 76 · cited 1×
“It has been reported that cultured cancer cells may require up to 100-fold molar excess of glutamine compared to other amino acids [11] and glutamine deprivation from the tumor environment has been found in a variety of tumorigenic contexts [12,13].”
BackgroundXiang, Z.-L., Zeng, Z.-C., Fan, J., Tang, Z.-Y., He, J., Zeng, H.-Y., & Chang, J. Y. (2012) · Molecular Biology Reports · doi:10.1007/s11033-011-0949-1 · Cited by 52
Cited by
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 499
Self-citationMitochondria Targeting as an Effective Strategy for Cancer Therapy
Ghosh, P., Vidal, C., Dey, S., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093363 · Cited by 263
Bouhamida, E., Morciano, G., Perrone, M., Kahsay, A. E., Della Sala, M., Wieckowski, M. R., Fiorica, F., Pinton, P., Giorgi, C., & Patergnani, S. (2022) · Biology · doi:10.3390/biology11020300 · Cited by 87
Chen, H., Wu, Q., Peng, L., Cao, T., Deng, M.-L., Liu, Y.-W., Huang, J., Hu, Y., Fu, N., Zhou, K.-B., et al. (2021) · Journal of Nanomaterials · doi:10.1155/2021/5164100 · Cited by 22
“The product is then transported to tumor cells, enters the tumor cell mitochondria, provides fuel for the TCA cycle, and generates a large amount of ATP through oxidative phosphorylation, which promotes tumor cell proliferation and resists apoptosis [18, 19].”
BackgroundXu, J., Guan, X., Jia, X., Li, H., Chen, R., & Lu, Y. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100255 · Cited by 19
“The results showed that acetylation was globally suppressed in HCC tumors, whichmaypartly be due to the impairment of TCAand the reduced level of acetyl-CoA in HCC (46).”
Background
Metadata
- Authors
- Todisco, S., Convertini, P., Iacobazzi, V., & Infantino, V.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-12-25
- Volume
- 12
- Issue
- 1
- Pages
- 68
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2997191693
- Cited by
- 103
- References
- 41
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.